ABBV-951
| ABBV-951 is subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease. |
Type of Molecule
Small MoleculeTarget
Dopamine ReceptorProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Parkinson's Disease | n/a |
Phase 3
|